Identifying potential tumor markers and antigens by database mining and rapid expression screening.

Genes expressed specifically in malignant tissue may have potential as therapeutic targets but have been difficult to locate for most cancers. The information hidden within certain public databases can reveal RNA transcripts specifically expressed in transformed tissue. To be useful, database information must be verified and a more complete pattern of tissue expression must be demonstrated. We tested database mining plus rapid screening by fluorescent-PCR expression comparison (F-PEC) as an approach to locate candidate brain tumor antigens. Cancer Genome Anatomy Project (CGAP) data was mined for genes highly expressed in glioblastoma multiforme. From 13 mined genes, seven showed potential as possible tumor markers or antigens as determined by further expression profiling. Now that large-scale expression information is readily available for many of the commonly occurring cancers, other candidate tumor markers or antigens could be located and evaluated with this approach.

[1]  E. Sage,et al.  The biology of SPARC, a protein that modulates cell‐matrix interactions , 1994, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[2]  J. Siegfried,et al.  Evidence for autocrine actions of neuromedin B and gastrin-releasing peptide in non-small cell lung cancer. , 1999, Pulmonary pharmacology & therapeutics.

[3]  J. Kononen,et al.  Tissue microarrays for high-throughput molecular profiling of tumor specimens , 1998, Nature Medicine.

[4]  Ji Huang,et al.  [Serial analysis of gene expression]. , 2002, Yi chuan = Hereditas.

[5]  H. Moch,et al.  High-throughput tissue microarray analysis to evaluate genes uncovered by cDNA microarray screening in renal cell carcinoma. , 1999, The American journal of pathology.

[6]  L. Liotta,et al.  Laser-capture microdissection: opening the microscopic frontier to molecular analysis. , 1998, Trends in genetics : TIG.

[7]  J. Craig Venter,et al.  Rapid cDNA sequencing (expressed sequence tags) from a directionally cloned human infant brain cDNA library , 1993, Nature Genetics.

[8]  S. Altschul,et al.  A public database for gene expression in human cancers. , 1999, Cancer research.

[9]  E. Sage,et al.  Regulation of angiogenesis by SPARC and angiostatin: implications for tumor cell biology. , 1996, Seminars in cancer biology.

[10]  D. Lockhart,et al.  Expression monitoring by hybridization to high-density oligonucleotide arrays , 1996, Nature Biotechnology.

[11]  C. Denef,et al.  Expression of the genes encoding bombesin-related peptides and their receptors in anterior pituitary tissue , 1993, Molecular and Cellular Endocrinology.

[12]  J. Greenfield,et al.  The Sec61 complex is located in both the ER and the ER-Golgi intermediate compartment. , 1999, Journal of cell science.

[13]  Y. Sugiyama,et al.  cDNA cloning and inducible expression of human multidrug resistance associated protein 3 (MRP3). , 1998, FEBS letters.

[14]  E. Sprinzak,et al.  Prediction of gene function by genome-scale expression analysis: prostate cancer-associated genes. , 1999, Genome research.

[15]  N. Ajubi,et al.  nmb, a novel gene, is expressed in low‐metastatic human melanoma cell lines and xenografts , 1995, International journal of cancer.

[16]  S. Rempel,et al.  SPARC: a potential diagnostic marker of invasive meningiomas. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[17]  S. Walker,et al.  Quantitative RT-PCR : Pitfalls and Potential , 1999 .

[18]  J. Wu.  Review of circulating tumor markers: from enzyme, carcinoembryonic protein to oncogene and suppressor gene. , 1999, Annals of clinical and laboratory science.

[19]  Y S Erozan,et al.  Microsatellite alterations as clonal markers for the detection of human cancer. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[20]  R. Panchal,et al.  Novel therapeutic strategies to selectively kill cancer cells. , 1998, Biochemical pharmacology.

[21]  Ronald W. Davis,et al.  Quantitative Monitoring of Gene Expression Patterns with a Complementary DNA Microarray , 1995, Science.

[22]  K. Kinzler,et al.  Identification of ras oncogene mutations in the stool of patients with curable colorectal tumors. , 1992, Science.

[23]  Tumour serum markers: clinical and economical aspects. , 1996, Anticancer research.

[24]  Itzhak D. Goldberg,et al.  Regulation of Angiogenesis , 1996, Experientia Supplementum.

[25]  E. Spindel,et al.  Molecular cloning of cDNAs encoding the human bombesin-like peptide neuromedin B. Chromosomal localization and comparison to cDNAs encoding its amphibian homolog ranatensin. , 1988, The Journal of biological chemistry.

[26]  T. B. Morrison,et al.  Quantification of low-copy transcripts by continuous SYBR Green I monitoring during amplification. , 1998, BioTechniques.

[27]  C. Wittwer,et al.  Continuous fluorescence monitoring of rapid cycle DNA amplification. , 1997, BioTechniques.

[28]  O. Podhajcer,et al.  Suppression of SPARC expression by antisense RNA abrogates the tumorigenicity of human melanoma cells , 1997, Nature Medicine.

[29]  L. Bain,et al.  Expression of multidrug resistance protein-3 (multispecific organic anion transporter-D) in human embryonic kidney 293 cells confers resistance to anticancer agents. , 1999, Cancer research.

[30]  M. Trudeau,et al.  Evaluation of HER-2/neu (erbB-2) status in breast cancer: from bench to bedside. , 1999, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[31]  Carol A. Dahl,et al.  New opportunities for uncovering the molecular basis of cancer , 1997, Nature Genetics.

[32]  T. Mikkelsen,et al.  SPARC: a signal of astrocytic neoplastic transformation and reactive response in human primary and xenograft gliomas. , 1998, Journal of neuropathology and experimental neurology.

[33]  Y. Sugiyama,et al.  cDNA cloning and inducible expression of human multidrug resistance associated protein 3 (MRP3) 1 , 1998 .

[34]  E. Gilboa,et al.  Immunotherapy of cancer with dendritic-cell-based vaccines , 1998, Cancer Immunology, Immunotherapy.

[35]  G. Landes,et al.  Analysis of human transcriptomes , 1999, Nature Genetics.

[36]  K. Kinzler,et al.  Digital PCR. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[37]  P. Björck.  Development of dendritic cells and their use in tumor therapy. , 1999, Clinical immunology.

[38]  D. Avigan.  Dendritic cells: development, function and potential use for cancer immunotherapy. , 1999, Blood reviews.

[39]  R. Weinshilboum,et al.  Human liver nicotinamide N-methyltransferase. cDNA cloning, expression, and biochemical characterization. , 1994, The Journal of biological chemistry.

[40]  J. Browning,et al.  Cloning and expression of human lipocortin, a phospholipase A2 inhibitor with potential anti-inflammatory activity , 1986, Nature.

[41]  P. Kleihues,et al.  Primary and secondary glioblastomas: from concept to clinical diagnosis. , 1999, Neuro-oncology.

[42]  D. K. Robson,et al.  Pathology & Genetics. Tumours of the Nervous System. World Health Organisation Classification of Tumours. P. Kleihues and k. Cavenee (eds). IARC Press, Lyon, 2000. No. of pages: 314. ISBN: 92 832 2409 4 , 2001 .

[43]  G. Peters,et al.  MRP3, an organic anion transporter able to transport anti-cancer drugs. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[44]  C. Öbek,et al.  Tumor-associated hyaluronic acid: a new sensitive and specific urine marker for bladder cancer. , 1997, Cancer research.